The 3D bioprinting sector has failed to deliver on its expectations of providing solutions within the regenerative medicine industry. The reason that the bioprinting field is failing is due to technological limitations. Their shortcomings are either based on lack of processing speed, their inability to keep the cells intact and functional, as well as their limitation of creating the diversity that is needed to create a realistic human tissue. Beyond a realistic functionality of these tissues they also lack additional functionality (conditions or processes within the tissue itself).

The organisation
The first start-up to merge advanced electric, magnetic, & microfluidic biofabrication technology with novel cyborganic technology to create high throughput tissues & organs with embedded bioelectronics, biosensors, and therapeutic agents. The team brings business and industry experts together with academic experts. Together they have 50+ years of combined experience in research and corporate environment.

Business activities
The company focuses on the 4D biofabrication of realistic human tissues embedded with biosensors, bioelectronics and/or therapeutic agents. They can be used by researchers and developers to create a better understanding of diseases, for the development of new treatments, safety testing and improvement of existing treatments. It will increase development speed and time to market for important healthcare solutions. For scalability and more standardization in development, the proprietary advanced bioprinting platform that is currently under development will be used. Focus on:

• Manufacturing ready Prototype, 0-series,
• Sensor embedded In-vitro model: Manufacturing ready Prototype